Daniel Chevallard - Viracta Therapeutics COO CFO
| VIRXDelisted Stock | USD 0.03 0 7.38% |
Insider
Daniel Chevallard is COO CFO of Viracta Therapeutics
| Age | 44 |
| Phone | 858 400 8470 |
| Web | https://www.viracta.com |
Daniel Chevallard Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Chevallard against Viracta Therapeutics pink sheet is an integral part of due diligence when investing in Viracta Therapeutics. Daniel Chevallard insider activity provides valuable insight into whether Viracta Therapeutics is net buyers or sellers over its current business cycle. Note, Viracta Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Viracta Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Chevallard over a year ago Acquisition by Daniel Chevallard of 200000 shares of Viracta Therapeutics at 0.985 subject to Rule 16b-3 | ||
Daniel Chevallard over a year ago Acquisition by Daniel Chevallard of 6889 shares of Viracta Therapeutics subject to Rule 16b-3 | ||
Daniel Chevallard over a year ago Disposition of 3405 shares by Daniel Chevallard of Viracta Therapeutics at 0.7322 subject to Rule 16b-3 | ||
Daniel Chevallard over a year ago Disposition of 6889 shares by Daniel Chevallard of Viracta Therapeutics subject to Rule 16b-3 |
Viracta Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.572) % which means that it has lost $0.572 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0867) %, meaning that it created substantial loss on money invested by shareholders. Viracta Therapeutics' management efficiency ratios could be used to measure how well Viracta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Viracta Therapeutics currently holds 25.56 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Viracta Therapeutics has a current ratio of 11.72, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Viracta Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Viracta Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viracta Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viracta to invest in growth at high rates of return. When we think about Viracta Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Christian Heinis | Bicycle Therapeutics | N/A | |
| Jaume Pons | Alx Oncology Holdings | 58 | |
| Peter MBA | Alx Oncology Holdings | 62 | |
| Keith MD | X4 Pharmaceuticals | 54 | |
| Misbah Tahir | IGM Biosciences | 49 | |
| Mark OMahony | Leap Therapeutics | 54 | |
| Leone MBA | Tenaya Therapeutics | 62 | |
| Shinyu MD | IGM Biosciences | 55 | |
| Eric Olson | Tenaya Therapeutics | N/A | |
| John MD | Vincerx Pharma | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| HansGeorg Lerchen | Vincerx Pharma | N/A | |
| Sophia MD | Alx Oncology Holdings | 56 | |
| Christine Granfield | Leap Therapeutics | 57 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Jeffrey CPA | Rallybio Corp | 54 | |
| MBA MPH | Protara Therapeutics | 41 | |
| MSc MBA | Inozyme Pharma | 53 | |
| Thomas MD | Trevi Therapeutics | 72 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 |
Viracta Therapeutics Leadership Team
Elected by the shareholders, the Viracta Therapeutics' board of directors comprises two types of representatives: Viracta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viracta. The board's role is to monitor Viracta Therapeutics' management team and ensure that shareholders' interests are well served. Viracta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viracta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel CPA, COO, CFO | ||
| Cheryl Madsen, Senior Affairs | ||
| Daniel Chevallard, COO CFO | ||
| Thalia MD, CoFounder | ||
| Patric MBA, Senior Strategy | ||
| Ronald MD, CoFounder Consultant | ||
| George Hillman, CoFounder | ||
| Robert Williams, CoFounder | ||
| Robert McRae, Vice Alliances | ||
| Ayman ElGuindy, Chief Officer | ||
| Mark Rothera, President CEO | ||
| Stewart Brown, Senior Counsel | ||
| Susan MD, Scientific Consultant | ||
| Michael Faerm, Chief Officer | ||
| Lisa Rojkjaer, Chief Officer | ||
| Biljana PharmD, Senior Development |
Viracta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viracta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.09 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (3.02 M) | ||||
| Shares Outstanding | 39.74 M | ||||
| Shares Owned By Insiders | 2.98 % | ||||
| Shares Owned By Institutions | 39.80 % | ||||
| Number Of Shares Shorted | 246.03 K | ||||
| Price To Earning | 2.54 X | ||||
| Price To Book | 3.00 X | ||||
| EBITDA | (46.86 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Viracta Pink Sheet
If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |